Granem

Granem is an oral medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist used as an antiemetic. It is marketed in the European Union and is available by prescription only. Granisetron works by blocking serotonin receptors in the central nervous system to reduce nausea and vomiting associated with chemotherapy or surgery. Granem does not contain additional active ingredients and is supplied in tablet form.

Granem is indicated for the prevention of nausea and vomiting in specific clinical situations, particularly those related to cancer treatment and surgery.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) after general anesthesia. - Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated. - Administration before the start of chemotherapy or surgery to achieve optimal efficacy. - May be considered in patients who have experienced inadequate control with other antiemetics.

The safety profile of Granem reflects the typical effects observed with 5‑HT3 receptor antagonists, ranging from mild to rare serious events.

Common: - Headache, often mild and transient. - Constipation or mild abdominal discomfort. - Dizziness or light‑headedness, especially when standing quickly. - Fatigue or feeling unusually tired. - Dry mouth or altered taste sensation.

Serious: - Allergic reactions such as rash, itching, swelling, or hives. - Cardiac arrhythmias, including QT interval prolongation. - Severe constipation that may progress to bowel obstruction. - Rare serotonin syndrome when used with other serotonergic drugs. - Severe hypotension or shock in rare cases.

When prescribing Granem, clinicians consider several precautionary measures to ensure safe use and to identify patients who may require monitoring or alternative therapy.

- Assess cardiac history, especially for prolonged QT interval, before initiating therapy. - Use caution in patients with hepatic impairment, as metabolism may be reduced. - Monitor for signs of constipation; intervene early to prevent complications. - Evaluate for known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Consider potential serotonin syndrome when combined with serotonergic agents such as SSRIs or tramadol. - Use the lowest effective dose and limit duration in pregnant or breastfeeding women, given limited safety data.

Granem may interact with other medications, influencing its effectiveness or increasing the risk of adverse events.

Avoid: - Concomitant use with other QT‑prolonging drugs (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics). - Combination with monoamine oxidase inhibitors (MAOIs) due to potential serotonin excess.

Use with caution: - Selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), or tramadol, which may increase serotonin syndrome risk. - Antifungal agents such as ketoconazole that inhibit CYP3A4 metabolism. - Drugs that affect cardiac conduction, including certain calcium channel blockers. - Herbal supplements like St. John’s wort that may alter serotonergic activity.